Links


English version

Publikationen Daniel Legler

  1. Legler DF, Loetscher M, Jones SA, Dahinden CA, Arock M, Moser B. 1996. Expression of high- and low-affinity receptors for C3a on the human mast cell line, HMC-1. Eur J Immunol 26:753-758.
  2. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833-835.
  3. Stuber Roos R, Loetscher M, Legler DF, Clark-Lewis I, Baggiolini M, Moser B. 1997. Identification of CCR8, the receptor for the human CC chemokine I-309. J Biol Chem 272:17251-17254.
  4. Loetscher M, Amara A, Oberlin E, Brass N, Legler DF, Loetscher P, D'Apuzzo M, Meese E, Rousset D, Virelizier JL, Baggiolini M, Arenzana-Seisdedos F, Moser B. 1997. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr Biol 7:652-660.
  5. Legler DF, Loetscher M, Stuber Roos R, Clark-Lewis I, Baggiolini M, Moser B. 1998. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 187:655-660.
  6. Willimann K*, Legler DF*, Loetscher M, Stuber Roos R, Delgado MB, Clark-Lewis I, Baggiolini M, Moser B. 1998. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28:2025-2034.

    * are both considered as first authors
  7. Arenzana-Seisdedos F, Amara A, Thomas D, Virelizier JL, Baleux F, Clark-Lewis I, Legler DF, Moser B, Baggiolini M. 1998. β-chemokine MDC and HIV-1 infection. Science 281:487a.
  8. Brandes M, Legler DF, Spoerri B, Schaerli P, Moser B. 2000. Activation-dependent modulation of B lymphocyte migration to chemokines. Int Immunol 12:1285-1292.
  9. Wehrli N, Legler DF, Finke D, Toellner KM, Loetscher P, Baggiolini M, Mac-Lennan ICM, Acha-Orbea H. 2001. Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur J Immunol 31:609-616.
  10. Legler DF, Wiedle G, Ross FP, Imhof BA. 2001. Superactivation of integrin αvβ3 by low agonist concentrations. J Cell Sci 114:1545-1553.
  11. Doucey MA, Legler DF, Boucheron N, Cerottini JC, Bron C, Luescher IF. 2001. CTL activation is induced by cross-linking of TCR/MHC-peptide - CD8/p56Lck adducts in rafts. Eur J Immunol 31:1561-1570.
  12. Legler DF, Doucey MA, Cerottini JC, Bron C, Luescher IF. 2001. Selective inhibition of CTL activation by a dipalmitoyl-phospholipid that prevents the recruitment of signaling molecules to lipid rafts. FASEB J 15:1601-1603, and FASEB J express article online
  13. Rothenberger S, Rousseaux M, Knecht H, Bender FC, Legler DF, Bron C. 2002. Association of the Epstein-Barr virus Latent membrane protein 1 with lipid rafts is mediated through its N-terminal region. Cell Mol Life Sci 59:171-180.
  14. Gaide O, Favier B, Legler DF, Bonnet D, Brissoni B, Valitutti S, Bron C, Tschopp J, Thome M. 2002. Carma1 is a critical lipid raft-associated regulator of TCR-induced NF-κB activation. Nat Immunol 3:836-843.
  15. Guillaume P, Legler DF, Boucheron N, Doucey MA, Cerottini JC, Luescher IF. 2003. Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J Biol Chem 278:4500-4509.
  16. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. 2003. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 18:655-664.
  17. Doucey MA, Legler DF, Faroudi M, Boucheron N, Baumgartner P, Naeher D, Cebecauer M, Hudrisier D, Ruegg C, Palmer E, Valitutti S, Bron C, Luescher IF. 2003. The β1 and β3 integrins promote T cell receptor-mediated cytotoxic T lymphocyte activation. J Biol Chem 278:26983-26991.
  18. Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, Ludewig B, Groettrup, M. 2004. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103:1595-1601.
  19. Legler DF, Johnson-Leger C, Wiedle G, Bron C, Imhof BA. 2004. The αvβ3 integrin as a tumor homing ligand for lymphocytes. EurJ Immunol 34:1608-1616.
  20. Stuermer CAO, Langhorst MF, Wiechers M, Legler DF, Hannbeck S, Guse AH, Plattner H. 2004. PrPc capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction. FASEB J 18:1731-1733, and FASEB J express article online
  21. Legler DF, Doucey MA, Schneider P, Chapatte L, Bender FC, Bron C. 2005. Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. FASEB J 19:1-3, and FASEB J express article online
  22. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. 2006. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176:966-973.
  23. Nachbur U, Kassahn D, Yousefi S, Legler DF, Brunner T. 2006. Posttranscriptional regulation of Fas (CD95) ligand activity by lipid rafts. Blood 107:2790-2796.
  24. Langhorst MF, Reuter A, Luxenhofer G, Boneberg EM, Legler DF, Plattner H, Stuermer CAO. 2006. Preformed reggie/flotillin caps: stable priming platforms for macrodomain assembly in T cells. FASEB J 20:711-713, and FASEB J express article online
  25. Otero C, Groettrup M, Legler DF. 2006. Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 177:2314-2323.
  26. Schlosser E, Otero C, Wünsch C, Kessler BM, Edelmann M, Brunisholz R, Drexler I, Legler DF*, Groettrup M*. 2007. A novel cytosolic class I antigen-processing pathway for endoplasmic-reticulum-targeted proteins. EMBO Rep 8:945-951. * share senior authorship
  27. Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF. 2007. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leuk Biol 82(5):1106-1114.
  28. Uetz-von Allmen E, Koch M, Fritz G, Legler DF. 2008. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 68:748-758.
  29. Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. 2008. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27:6068-6074.
  30. Segura JM, Guillaume P, Mark S, Dojcinovic D, Johannsen A, Bosshard G, Angelov G, Legler DF, Vogel H, Luescher IF. 2008. Increased mobility of major histocompatibility complex I-peptide complexes decreases the sensitivity of antigen recognition. J Biol Chem 283:24254-24263.
  31. Boneberg EM, Legler DF, Senn HJ, Fürstenberger G. 2008. Reduced expression of cyclooxygenase-2 in primary breast cancer. J Natl Cancer Inst 100:1042-1043.
  32. Otero C, Eisele PS, Schaeuble K, Groettrup M, Legler DF. 2008. Distinct motifs of the chemokine receptor CCR7 regulate signal transduction, receptor trafficking, and chemotaxis. J Cell Sci 121:2759-2767.
  33. Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M, Legler DF. 2009. Prostaglandin E(2) enhances T cell proliferation by inducing the co-stimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 113(11):2451-2460.
  34. Boneberg EM, Legler DF, Hoefer MM, Ohlschlegel C, Steininger H, Füzesi L, Beer GM, Dupont-Lampert V, Otto F, Senn HJ, Fürstenberger G. 2009. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer 101(4):605-614.
  35. Boneberg EM, Illges H, Legler DF, Fürstenberger G. 2009. Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process. Microvasc Res 78(3):325-31.
  36. Legler DF, Bruckner M, Uetz-von Allmen E, Krause P. 2010. Prostaglandin E(2) at new glance: Novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 42(2):198-201.
  37. Schumann K, Lämmermann T, Bruckner M, Legler DF, Polleux J, Spatz JP, Schuler G, Förster R, Lutz MB, Sorokin L, Sixt M. 2010. Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity 32(5):703-713.
  38. Metzner C, Legler DF, Dangerfield JA. 2010. Surface engineering of biomembranes with glycosylphosphatidylinositol-anchored proteins and its applications. In GPI membrane anchors-the much needed link. Ed Dangerfield JA, Metzner C. Bentham e-book Chapter 6: 83-97. eISBN: 978-1-60805-123-6, 2010
  39. Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF. 2010. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgenic mice. J Immunol 185:3445-3455.
  40. Schaeuble K, Hauser MA, Singer E, Groettrup M, Legler DF. 2011. Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol 187(11):5645-52.

 BITg

Biotechnologie Institut Thurgau
an der Universität Konstanz
Unterseestrasse 47
CH-8280 Kreuzlingen
Schweiz
Fon +41 (0)71 678 5020
Fax +41  (0)71 678 5021
 DNA_BITg

© 2010.    Nach oben